An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)

大多数胃癌（GC）病例是在晚期发现的，此时患者的平均预期寿命约为一年。在症状前阶段（通常是慢性胃部炎症）诊断有胃癌风险的人，可以显著改善预后。人工智能（AI）可以通过自动化大部分治疗和分析来帮助临床医生理解他们自己的数据，这些治疗和分析需要手工工作和多年的经验。但它可以做得更多：它可以将来自不同来源的可用数据汇集到一个庞大的数据湖中，并将这些数据交叉关联，得出胃癌的“风险评分”，并阐明其进化机制。Aida的目标就是做到这一点。它有助于研究人员了解胃癌发生的机制，帮助临床医生在尽可能早的阶段诊断癌前炎症，为治疗和随访提供个性化的治疗策略，并为监测患者的健康状况提供个性化的建议，从而有助于胃癌的预防。这使阿依达完全列入了欧洲“在快速变化的社会中保持健康”的议程。Aida联合了欧洲在胃炎、胃癌领域的一些领先权威、领先的人工智能和机器学习专家、数据治理和隐私方面的专家、公共管理代表和患者倡导者。阿依达也与该行业有着紧密的联系。项目结束后，研究结果将在一个基金会中继续存在，该基金会将作为慢性胃炎和胃癌的跨国焦点。我们希望Aida坚实、包容的设计原则、它的社会相关性和耐久性将围绕慢性胃炎、它的理解和治疗产生一个充满活力的生态系统。我们希望它能激发健康领域的其他数据合作——其他慢性炎症、其他形式的癌症或其他疾病。

Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether.